問卷

TPIDB > Search Result

Search Result

篩選

List

2394Cases

2018-06-01 - 2022-06-01

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2018-03-20 - 2023-08-08

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2011-09-01 - 2016-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2013-06-01 - 2015-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-05-31 - 2015-06-01

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-01-14 - 2017-01-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2014-11-01 - 2016-11-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-01-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2013-09-01 - 2020-06-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2020-08-31 - 2026-03-31

Phase III

A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
  • Condition/Disease

    Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

  • Test Drug

    Oregovomab

Participate Sites
6Sites

Recruiting6Sites